TS-066912 — Targeted humanized mAbs and ADCs for cancer treatment

TS-066773 — The Need Cardiomyopathy, a disease of the heart muscle, poses significant public health challenges due to its diverse causes, symptoms, and potential complications, including heart failure and arrhythmias. With cardiomyopathy often induced by drugs, such as anthracyclines used in chemotherapy, ther…

TS-066770 — The Need In the realm of human and mammalian health, delivering biologically active components that are sensitive to moisture or other environmental factors has posed a significant challenge. Traditional methods, such as encapsulation or use of desiccants, often fall short in ensuring stability and…

TS-066751 — In the rapidly evolving field of biotechnology and pharmaceuticals, there is a critical need for efficient delivery mechanisms to transport therapeutic agents directly into cells. Traditional methods face challenges with membrane impermeability and degradation of therapeutic compounds, limiting th…

TS-066750 — The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted global health and economies. Despite vaccine efforts, issues such as vaccine hesitancy, delays in distribution, and emerging variants have highlighted the need for effective therapeutic interventions. These i…

TS-066100 — Research tool to transfect cells ex vivo using electroporation through electrospun core-shell fibers for research applications

TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.

TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.

TS-065913 — Gene therapy strategies for treating peripheral neuropathy.

TS-065862 — The Need In the landscape of cancer treatment, the emergence of immunotherapy has shown remarkable promise. However, its efficacy is not universal across all cancer types, and resistance development poses a significant challenge. Hyperprogression, characterized by accelerated tumor growth, further …

TS-065860 — The Need: Cancer remains one of the most pressing medical challenges of our time, demanding innovative solutions to enhance treatment efficacy while minimizing systemic toxicity. Conventional chemotherapy agents often suffer from poor solubility, instability, and indiscriminate cytotoxicity, necessi…

TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.

TS-065789 — Using tissue nano-transfection to reprogram skin cells to treat diabetes, obesity and/or cardiovascular health

TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.

TS-065460 — The Need Cancer remains one of the most pressing medical challenges worldwide, necessitating novel therapeutic approaches to combat its proliferation. Despite advancements, targeted therapies are often limited by immune responses or cumbersome production processes. There's a growing demand for …

TS-065459 — The Need The emergence of HIV-1 infection continues to pose significant challenges in healthcare worldwide. Current treatment approaches primarily target viral components, leading to the development of drug resistance over time. There is a pressing need for innovative therapeutic strategies that di…

TS-065457 — The Need: In the realm of therapeutic development, there's a pressing need for precise targeting of dysregulated ribonucleoprotein (RNP) complexes to combat various diseases, particularly neurodegenerative disorders like ALS, Alzheimer’s, and Huntington’s diseases. Traditional metho…

TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.

TS-065154 — , 2018-345 Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.

TS-064581 — Antibodies are essential therapeutic modalities for treating a plethora of different diseases, ranging from cancer, autoimmune disorders, degenerative diseases, and inflammation. The FDA approved the first antibody over three decades ago, and since more than 570 have been studied in clinical trials,…